Sir Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension, which has discovered over 1000 gene loci for blood pressure. He was Director of the William Harvey Research Institute between 2002 and 2020 and was elected a Fellow of the Academy of Medical Sciences in 2008. Since 2008 he directs the National Institute for Health Research Cardiovascular Biomedical Research Unit and Centre at Barts. Between 2010 and 2015 he co-led the merger of three hospitals in North London to create the new £400 million Barts Heart Centre. He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018. In 2013 he became an NIHR Senior Investigator and was Chief Scientist for Genomics England (100,000 Genomes Project) between 2013 until 2021. Sir Mark was awarded a Knighthood in the June 2019 Queen’s Birthday Honours List for services to the 100,000 Genomes Project. He cocreated the National Genomic Test Directory and the Genomic Medicine Service bringing equity of access to genomic testing across 56 million people. Sir Mark is now Chief Executive of Barts Life Sciences, which is a £600 million Life Science expansion of Queen Mary University of London, Barts Health, and industrial partnerships in 1 million square feet of space in Whitechapel.